Clovis Oncology Long-Term Investments

Clovis Oncology posts a long-term investments of $240M as of September 2022. That compares with $280M in the prior-year period — down 11.8% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Clovis Oncology's long-term investments was $280M. The latest reading is $240M — a 11.8% year-over-year decrease (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

Long-Term Investments is one piece of Clovis Oncology's financial statement story. At $240M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CLVS's long-term investments usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Clovis Oncology's other metric pages and overview cover the third.

Judging Clovis Oncology against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in long-term investments easier to interpret. Start with $240M here, then scan peer and history charts to see if the gap is persistent.